MX2023015121A - Metodos de uso de inhibidores de aldosterona sintasa. - Google Patents

Metodos de uso de inhibidores de aldosterona sintasa.

Info

Publication number
MX2023015121A
MX2023015121A MX2023015121A MX2023015121A MX2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A
Authority
MX
Mexico
Prior art keywords
aldosterone synthase
methods
synthase inhibitors
subject
compound
Prior art date
Application number
MX2023015121A
Other languages
English (en)
Spanish (es)
Inventor
Brian Murphy
Mary Bond
Catherine Pearce
Original Assignee
Cincor Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincor Pharma Inc filed Critical Cincor Pharma Inc
Publication of MX2023015121A publication Critical patent/MX2023015121A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023015121A 2021-06-24 2022-06-24 Metodos de uso de inhibidores de aldosterona sintasa. MX2023015121A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214521P 2021-06-24 2021-06-24
US202163290364P 2021-12-16 2021-12-16
PCT/US2022/073148 WO2022272300A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
MX2023015121A true MX2023015121A (es) 2024-04-16

Family

ID=84545863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015121A MX2023015121A (es) 2021-06-24 2022-06-24 Metodos de uso de inhibidores de aldosterona sintasa.

Country Status (10)

Country Link
US (1) US20240277698A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358959A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523559A (cg-RX-API-DMAC7.html)
KR (1) KR20240035483A (cg-RX-API-DMAC7.html)
AU (2) AU2022299103B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023027025A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223211A1 (cg-RX-API-DMAC7.html)
IL (1) IL309428A (cg-RX-API-DMAC7.html)
MX (1) MX2023015121A (cg-RX-API-DMAC7.html)
WO (1) WO2022272300A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026521801A (ja) * 2023-06-29 2026-07-01 アストラゼネカ アイルランド リミテッド バクスドロスタットの結晶形、並びにその製造方法及びその使用
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
IL329013A (en) * 2023-12-15 2026-08-01 Astrazeneca Ireland Ltd SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension
WO2026120166A1 (en) 2024-12-06 2026-06-11 AstraZeneca Ireland Limited Tablet formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AU4866196A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
CA2832996C (en) * 2011-04-26 2019-05-07 Merck Sharp & Dohme Corp. Tricyclic triazole compounds and their use as aldosterone synthase inhibitors
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Also Published As

Publication number Publication date
EP4358959A1 (en) 2024-05-01
CA3223211A1 (en) 2022-12-29
WO2022272300A1 (en) 2022-12-29
IL309428A (en) 2024-02-01
KR20240035483A (ko) 2024-03-15
US20240277698A1 (en) 2024-08-22
JP2024523559A (ja) 2024-06-28
AU2026201954A1 (en) 2026-04-02
AU2022299103A1 (en) 2024-01-25
EP4358959A4 (en) 2025-05-14
BR112023027025A2 (pt) 2024-03-12
AU2022299103B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
MX2024008551A (es) Terapias de combinacion.
MX2021009562A (es) Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
BR112022022634A2 (pt) Inibidores de atr para o tratamento de câncer
MX2021002804A (es) Terapias de combinacion.
SV2011003853A (es) Compuestos organicos
EA201291309A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОДНИХ И В КОМБИНАЦИИ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
BR112023027025A2 (pt) Métodos de uso de inibidores da aldosterona sintase
AR075501A1 (es) Uso de inhibidores de la succinato deshidrogenasa para combatir infecciones primarias por oidio
NI201100048A (es) Aminotriazolopiridinas y su uso como inhibidores de la cinasa.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
MX2022001004A (es) Inhibidores de enzimas.
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
CO2022000270A2 (es) Inhibidores de enzimas
CO2025005378A2 (es) Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido)carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso
CL2022001353A1 (es) Inhibidores de egfr
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CO2022000266A2 (es) Inhibidores de enzimas
AR074214A1 (es) Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensiblizantes al ca2+ para el tratamiento de la cardiomiopatia hipertrofica
CL2022003400A1 (es) Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe
CL2010001618A1 (es) Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades.